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Medication Use Evaluation of Vaccines in Patients With Asplenia
Clarence Kyle Walker, PharmD; Jarrod Kile, RPh, BCPS 
Lehigh Valley Health Network, Allentown, PA
Background
•  Patients with asplenia are at an increased risk for 
infections by encapsulated organisms within the first 
2 years post splenectomy. The most common of 
these organisms include Streptococcus pneumoniae, 
Haemophilus influenzae type b, and Neisseria 
meningitidis.
•  Current IDSA and CDC guidelines recommend initial 
vaccination with Pneumococcal conjugate vaccine 
(PCV13, Prevnar®), Haemophilus Influenzae type b 
(Hib), Meningococcal (Groups A,C,Y and W-135) 
Polysaccharide Diphtheria Toxoid Conjugate (Menactra®), 
and Meningococcal Group B (Bexsero®) or 
Meningococcal Group B factor H binding protein 
(Trumemba®) either 2 weeks prior to elective 
splenectomy or within 2 weeks post-emergent 
splenectomy.
•  Practice at Lehigh Valley Health Network (LVHN)
   Adult patients that are scheduled to undergo 
elective splenectomy are encouraged to receive the 
recommended vaccines >2 weeks prior to surgery
   Adult patients that are admitted for emergent 
splenectomy due to trauma are given the vaccines 
prior to discharge from the hospital. 
   All patients that undergo splenectomy are 
encouraged to follow up at 8 weeks post-op to 
receive PPSV23, MenACWY, and MenB-4C. 
Objective 
•  Review vaccination practices in patients post-
splenectomy at Lehigh Valley Hospital–Cedar Crest 
(LVH–CC) and affiliated outpatient clinics to identify 
areas for improvement
Methods:
•  Retrospective electronic medical record review of 
patients admitted to LVH–CC from Aug. 1, 2015 
through Aug. 31, 2019 who underwent either  
elective or emergent splenectomy 
   Patients were excluded from analysis if:
    < 18 years old
    No documentation of immunizations in their 
electronic medical record
•  Following information was abstracted from patient 
charts: age, gender, LVHN primary care physician 
(PCP) (yes/no), type of splenectomy surgery 
(emergency vs elective), vaccines administered up  
to 8 weeks prior to elective splenectomy, vaccines 
administered up to 1-year post-splenectomy, and  
the location of vaccine administration. 
Results
•  95 patients met inclusion criteria
   18 patients excluded due to no documentation of 
immunizations (15 patients who underwent elective and  
3 patients who underwent emergency splenectomy)
Table 1. Baseline characteristics
Elective Emergency
 n (%)
Total Cases (N=77) 59 (78) 18 (22)
Female 42 (71) 3 (17)
LVHN PCP 39 (66) 5 (28)
Average ± Std Dev
Age (years) 57 ± 19.6 64 ± 17.9
LOS (days) 6.4 ± 7.7 16.6 ± 13.4
Table 2. Rates of appropriate vaccine administration (N=77)
Elective n=59 Emergency n=18
n (%)
All vaccines
Prior to surgery 18 (31) -
At least 2 weeks prior to surgery 15 (25) -
Prior to discharge 21 (36) 12 (67)
Follow-up vaccines
Within 8 weeks 23 (39) 0 (0)
Within 1 year 25 (42) 0 (0)
At least 1 follow-up vaccine 37 (63) 2 (11)
LVHN PCP 22 (59) 1 (50)
Non-LVHN PCP 15 (41) 1 (50)
Graph 1. Percentage of patients receiving all recommended 
vaccines
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Graph 2. Percentage of patients who received follow-up 
vaccines by location
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Conclusion
•  Low percentage of patients received vaccines prior to elective 
splenectomy
   Primary care offices do not routinely stock the necessary vaccines to 
administer prior to elective surgery
   An improvement in pre-surgical planning may increase vaccination rates 
•  High percentage of patients who underwent either elective or emergent 
splenectomy received at least three of the four recommended vaccines 
prior to discharge (83% and 94%, respectively). Greater percentage 
received all four vaccines following emergent splenectomy (67%).
   No trend exists for what vaccines were missed prior to discharge in 
either group
   Order set available targeting immunizations post-splenectomy for 
emergent procedure
   Consider incorporation of recommendations for patients undergoing 
elective procedures
•  Similar vaccination completion rates between patients with an LVHN vs 
Non-LVHN PCP (35% vs 44%)
•  Rate of vaccine completion within one year of surgery was lower than 
expected at 42%.
•  Results of this MUE provide evidence for much needed improvement in 
this area of vaccine administration.
   The results will be presented to the appropriate departments to help 
develop an action plan that will allow us to further align our practices 
with the current IDSA and CDC guidelines. 
disclosures
The authors have nothing to disclose concerning possible financial or personal relationships with commercial entities.
references
1 Bonanni P, et al. Recommended vaccinations for asplenic and hyposplenic adult patients. Hum Vaccin Immunother. 
2017;13(2):359-368.
2 Hammerquist R, et al. Vaccinations in asplenic adults. Am J Health Syst Pharm. 2016;73(9):e220-e228.
3 Mourtzoukou EG, et al. Vaccination of asplenic or hyposplenic adults. Br J Surg. 2008;95(3):273-280.
4 Rubin LG, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 
2013;58(3):309-318.
5 Centers for Disease Control and Prevention. Charter of the Advisory Committee on Immunization Practices. Updated 1 
April 2018. Accessed at www.cdc.gov/vaccines/acip/committee/acip-charter.pdf on 7 November 2019.
6 Kobayashi M, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944-947.
7 Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate 
vaccines---Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 
2011;60(3):72-76.
